scispace - formally typeset
Open AccessJournal ArticleDOI

Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes

Reads0
Chats0
TLDR
It is believed that the most important consideration is to select antidiabetes agents that correct specific pathophysiologic disturbances present in T2DM and that have complementary mechanisms of action.
Abstract
Two general approaches to the treatment of type 2 diabetes mellitus (T2DM) have been advocated. 1 ) A “guideline” approach that advocates sequential addition of antidiabetes agents with “more established use” (1); this approach more appropriately should be called the “treat to failure” approach, and deficiencies with this approach have been discussed (2). And 2 ) a “pathophysiologic” approach using initial combination therapy with agents known to correct established pathophysiologic defects in T2DM (3). Within the pathophysiologic approach, choice of antidiabetes agents should take into account the patient’s general health status and associated medical disorders. This individualized approach, which we refer to as the ABCD(E) of diabetes treatment (4), has been incorporated into the updated American Diabetes Association (ADA) guidelines (5). Even though physicians must be cognizant of these associated conditions (ABCDE) when initiating therapy in newly diagnosed T2DM patients, we believe that the most important consideration is to select antidiabetes agents that correct specific pathophysiologic disturbances present in T2DM and that have complementary mechanisms of action. Although it has been argued that the pathogenesis of T2DM differs in different ethnic groups (6), evidence to support this is weak. Although the relative contributions of β-cell failure and insulin resistance to development of glucose intolerance may differ in different ethnic groups (6), the core defects of insulin resistance in muscle/liver/adipocytes and progressive β-cell failure (3) are present in virtually all T2DM patients and must be treated aggressively to prevent the relentless rise in HbA1c that is characteristic of T2DM. In subsequent sections, we provide a review of the natural history of T2DM, specific pathophysiologic abnormalities responsible for T2DM, currently …

read more

Citations
More filters
Journal ArticleDOI

Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation

TL;DR: This review summarises the biochemical, histological and macromolecular changes that contribute to oxidative liver damage among diabetic individuals.
Journal ArticleDOI

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema

TL;DR: An urgent call is issued for the review of the current DM classification system toward the consensus on a new, more useful system that obviates the inherent and unintended confusions.
Journal ArticleDOI

Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

TL;DR: In adults at risk for diabetes, LSM and medications (weight loss and insulin-sensitizing agents) successfully reduced diabetes incidence, suggesting that interventions to preserve effects are needed.
References
More filters
Journal ArticleDOI

Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects

TL;DR: It is demonstrated that the maximum tubular reabsorption capacity for glucose (Tmo) is significantly increased in young patients with diabetes of short duration and GFR is also significantlyIncreased in diabetics.
Journal ArticleDOI

IS THE COMBINATION OF SULFONYLUREAS AND METFORMIN ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR DISEASE OR ALL-CAUSE MORTALITY? A Meta-Analysis of Observational Studies

TL;DR: The combination therapy of metformin and sulfonylurea significantly increased the RR of the composite end point of cardiovascular hospitalization or mortality irrespective of the reference group, however, there were no significant effects of this combination therapy on either CVD mortality or all-cause mortality alone.
Journal ArticleDOI

Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT

TL;DR: The favorable combined changes in β-cell function and insulin sensitivity over time with rosiglitazone appear to be responsible for its superior glycemic durability over metformin and glyburide as initial monotherapy in type 2 diabetes.
Journal ArticleDOI

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

TL;DR: The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA1c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years.
Journal ArticleDOI

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study

TL;DR: Low-dose combination therapy with rosiglitazone and metformin was highly effective in prevention of type 2 diabetes in patients with impaired glucose tolerance, with little effect on the clinically relevant adverse events of these two drugs.
Related Papers (5)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 -